Small-molecule TLR3 agonist adjuvant PVP-057 with scalable green-chemistry synthesis

Technology
In development
University
Scouted & summarized by Halo AI

PVP-057 is a synthetic, small-molecule TLR3 agonist adjuvant that enhances vaccine-induced immune responses. Developed by the Precision Vaccines Program at Boston Children’s Hospital, it features a scalable, green-chemistry synthesis process and demonstrates robust immunomodulatory activity comparable to clinical standards in preclinical models.

Overview

PVP-057 is a novel, fully synthetic small-molecule Toll-like receptor 3 (TLR3) agonist adjuvant developed to enhance immune responses in vaccine formulations. As an immunomodulator, it serves to elicit robust humoral and cellular immunity, showing effectiveness comparable to clinical-grade benchmarks like AS01B. Its development utilized a green chemistry approach, emphasizing scalability, reduced waste, and cost-efficiency. The compound offers potential prophylactic and therapeutic applications beyond vaccinology, including roles in immune-oncology and the treatment of conditions such as atherosclerosis and arterial injury.

Technical specifications
  • Mechanism: Selective activation of both human and mouse TLR3.
  • Synthesis: A streamlined, three-step, 24-hour green chemistry synthesis scheme starting from commercially available materials.
  • Scalability: The production process has been demonstrated at scales up to 1 gram with high reproducibility and approximately 98% purity.
  • Stability: The lyophilized pharmacophore remains stable at 4 degrees Celsius or colder for extended periods.
  • Performance: Induces a mixed Th1/Th2 immune profile and supports long-term immunogenicity for antigens such as the varicella-zoster virus glycoprotein E.
Technology readiness level

The technology is currently in the research and preclinical development stage. It has been validated in mouse models, demonstrating successful immune response induction in both intradermal and intramuscular administration routes. While it has established robust performance in laboratory settings and defined a scalable, high-purity synthesis process, it has not yet reached clinical deployment or commercial availability for human use. Therefore, it is assessed at TRL 4.

Generated Nov 15, 2026. Please verify key information.

About Children's Hospital Boston

Boston Children’s Hospital (formerly Children’s Hospital Boston) is a major pediatric teaching hospital and research enterprise in Boston’s Longwood Medical Area. Industry collaboration is enabled by co-located labs and shared core facilities embedded with clinical care, with established processes for sponsored research and clinical trials. Proximity to the Boston–Cambridge biotech cluster, together with affiliation to Harvard Medical School, provides access to collaborators and translational expertise. Research is supported by competitive federal funding, including the National Institutes of Health and other U.S. agencies. A dedicated tech transfer office and digital innovation program manage IP, licensing, startup formation, and collaboration agreements.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.